Theresa Wingrove - ImmunoGen Vice President - Regulatory Affairs and Quality
President
Dr. Theresa G. Wingrove, Ph.D serves as Vice President Regulatory Affairs and Quality of the company. She joined ImmunoGen in 2011, and has served as our Vice President, Regulatory Affairs and Quality since February 2017. Prior to that she served as Vice President, Regulatory Affairs from her date of hire to January 2017. Prior to joining ImmunoGen, she served as Vice President, Regulatory and Clinical Affairs, at Histogenics, Inc., a medical device company, from 2006 to 2011. Prior to that she served as Senior Director, Regulatory and Clinical Affairs, at MediSpectra, Inc., a medical device company, from 2000 to 2006. Prior to that she served in various regulatory and clinical management capacities at Infusaid Inc., a subsidiary of Pfizer Inc., a pharmaceutical company, from 1988 to 1999 since 2018.
| Age | 66 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 781 895 0600 |
| Web | https://www.immunogen.com |
Theresa Wingrove Latest Insider Activity
Tracking and analyzing the buying and selling activities of Theresa Wingrove against ImmunoGen stock is an integral part of due diligence when investing in ImmunoGen. Theresa Wingrove insider activity provides valuable insight into whether ImmunoGen is net buyers or sellers over its current business cycle. Note, ImmunoGen insiders must abide by specific rules, including filing SEC forms every time they buy or sell ImmunoGen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 27788 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 6792 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 166725 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 158641 shares of ImmunoGen subject to Rule 16b-3 |
ImmunoGen Management Efficiency
The company has return on total asset (ROA) of (0.0849) % which means that it has lost $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1988) %, meaning that it created substantial loss on money invested by shareholders. ImmunoGen's management efficiency ratios could be used to measure how well ImmunoGen manages its routine affairs as well as how well it operates its assets and liabilities.ImmunoGen currently holds 15.24 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. ImmunoGen has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ImmunoGen's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Erin MD | Terns Pharmaceuticals | 53 | |
| Gregory Zante | Viking Therapeutics | 53 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 |
ImmunoGen Leadership Team
Elected by the shareholders, the ImmunoGen's board of directors comprises two types of representatives: ImmunoGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmunoGen. The board's role is to monitor ImmunoGen's management team and ensure that shareholders' interests are well served. ImmunoGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmunoGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel JD, VP Officer | ||
| Susan Altschuller, VP CFO | ||
| MMSc MD, VP Officer | ||
| Lauren MBA, Senior Officer | ||
| Renee Lentini, VP Officer | ||
| Stacy Coen, Sr Officer | ||
| Audrey Bergan, Senior Officer | ||
| Courtney OKonek, Senior Relations | ||
| Isabel Kalofonos, Senior Officer | ||
| Anabel Chan, Head Relations | ||
| FACP MD, VP Affairs | ||
| Mark Enyedy, President CEO, Director | ||
| Theresa Wingrove, Vice President - Regulatory Affairs and Quality | ||
| Stacy MBA, Senior Officer |
ImmunoGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ImmunoGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 91.29 % | |||
| Number Of Shares Shorted | 20.61 M | |||
| Price To Earning | (4.49) X |
Pair Trading with ImmunoGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Simon Property could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Simon Property when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Simon Property - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Simon Property Group to buy it.
The correlation of Simon Property is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Simon Property moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Simon Property Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Simon Property can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |